US/UK/Canada

Share

Contacts

  • Bronwyn Brophy O'Connor

    CEO


    Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden
    http://www.vitrolifegroup.com
  • Patrik Tolf

    CFO


    Vitrolife AB (publ), Box 9080, 400 92 Göteborg, Sweden
    +46 31 766 90 21
    http://www.vitrolifegroup.com
  • Vitrolife AB
    +46 (0)31 721 80 00
    +46 (0)31 721 80 99
    http://www.vitrolifegroup.com

    • Links

    Pick a time period -
    Tags ( Active)

    Conference call full year report 2024

    Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the fourth quarter and full year report 2024. The presentation will be held in English.Time: Thursday 30 January, 2025 at 10.00 a.m. CET.To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy | Vitrolife Group 

    Patrik Tolf steps down as CFO of the Vitrolife Group - Helena Wennerström appointed acting CFO

    Vitrolife AB (publ) announces today that Patrik Tolf will be stepping down as Chief Financial Officer due to personal reasons. Helena Wennerström will assume the role of acting CFO. Helena has extensive experience in finance and business management, including having served as CFO at ViaCon Group AB and EVP & CFO at Bulten AB. "We are very pleased that Helena Wennerström is taking on the role of acting CFO. She will bring deep competence and a wealth of experience to the Vitrolife Group. I would like to take this opportunity to sincerely thank Patrik for his contributions to the company

    Interim report Q3, 2024: Improved growth with solid margins

    Third quarter · Sales of SEK 867 (848) million, an increase of 7% in local currencies and 2% in SEK. · Sales per region, in local currencies was +9% in EMEA, +2% in Americas and +9% in APAC. · Sales per business area, in local currencies was +13% in Consumables, +11% in Technologies and 0% in Genetics. · Gross margin increased to 58.6% (55.7). · Operating income before depreciation and amortisation (EBITDA) was SEK 289 (287) million, giving an EBITDA margin of 33.4% (33.9). · Operating cash flow decreased to SEK 206 million (214). · Net income was SEK 116 (122)

    Conference call interim report

    Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q3, 2024. The presentation will be held in English.Time: Thursday 24 October, 2024 at 10.00 a.m. CET. To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy | Vitrolife Group 

    Election committee for Vitrolife AB (publ)

    The following people have been appointed as members of the election committee for Vitrolife AB for the Annual General Meeting in 2025: Niels Jacobsen, appointed by William Demant Invest A/SPatrik Tigerschiöld, appointed by Bure Equity ABPatricia Hedelius, appointed by AMF Fonder & PensionJón Sigurdsson, Chairman of the Board The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife AB on April 25, 2024.The Annual General Meeting

    With a click of a mouse button: Artificial intelligence (AI) brings fast and objective embryo assessment to IVF

    World-first clinical study, published in Nature Medicine, demonstrates that a deep-learning AI software developed by Vitrolife Group (intelligent data analysis score: iDAScore®), which does not require human input, is 10x faster than standard manual assessment and provides similar clinical outcomes.Dr Peter Illingworth, Medical Director, Strategic Growth of Virtus Health and the Principal Investigator for the study said “The aim of the study was to determine if this particular AI tool could be used within IVF clinics to potentially improve workflow efficiency, without decreasing clinical

    Interim report Q2, 2024: Strong Technologies growth and improved margins

    Second quarter · Sales of SEK 941 (905) million, an increase of 4% in local currencies and 4% in SEK. · Sales per region, in local currencies was -5% in APAC, +11% in EMEA and +5% in Americas. · Sales growth per business area, in local currencies, was +3% in Consumables, +40% in Technologies and -7% in Genetics. · Gross margin increased to 59.9% (55.8). · Operating income before depreciation and amortisation (EBITDA) increased to SEK 327 (293) million, giving an EBITDA margin of 34.7% (32.4). · Operating cash flow increased to SEK 236 million (211). · Net income

    Conference call interim report

    Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q2, 2024. The presentation will be held in English.Time: Wednesday 17 July, 2024 at 10.00 a.m. CET. To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy | Vitrolife Group 

    Vitrolife AB (publ) completes the acquisition of eFertility

    Vitrolife AB (publ) has completed the acquisition of eFertility (STB Zorg B.V.) as previously communicated in the press release on 2 May 2024.eFertility is an innovative system and software company transforming IVF clinic management with its cutting-edge solutions: eWitness (witnessing system to track and trace each step of the IVF procedure) and eBase (a specialised EMR that is compatible with hospital information systems). eFertility has a leading presence in the Netherlands and is rapidly expanding across Europe. In 2023, the company had revenues of EUR 1.5 million with a strong sales

    Vitrolife AB (publ) acquires eFertility

    Vitrolife AB (publ) today signed an agreement to acquire 100% of the shares in eFertility (STB Zorg B.V.). This acquisition is a key element of the Vitrolife Group’s strategy to bring increased standardisation and digitalisation to IVF clinics around the world.eFertility is an innovative system and software company transforming IVF clinic management with its cutting-edge solutions: eWitness (witnessing system to track and trace each step of the IVF procedure) and eBase (a specialised EMR that is compatible with hospital information systems). eFertility has a leading presence in the

    Report from Annual General Meeting of Vitrolife AB (publ)

    At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: · Resolution in accordance with the Board’s proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the record day. · Re-election of Board members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee’s proposal. Jón Sigurdsson was elected Chairman of the Board. · Remuneration to the Board members is proposed to be in total SEK 3,300,000 of which SEK 1,200,

    Interim report Q1, 2024: Strong growth in APAC and solid margins

    First quarter · Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK. · Sales per region, in local currencies was +19% in APAC, -2% in EMEA and -14% in Americas. · Sales per business area, in local currencies was +12% in Consumables, +8% in Technologies and -12% in Genetics. · Gross margin increased to 57.1% (56.8). · Operating income before depreciation and amortisation (EBITDA) increased to SEK 272 (262) million, giving an EBITDA margin of 32.4% (30.6). · Operating cash flow increased to SEK 198 million (160). · Net income

    Correction: Notice to attend the Annual General Meeting of Vitrolife AB (publ)

    The correction concerns a clarification in the agenda that item 13 of the agenda also covers the election of an auditor.The shareholders of Vitrolife AB (publ), corporate identity number 556354-3452(‘the Company’) are hereby invited to attend the Annual General Meeting of shareholders on Thursday 25 April 2024 at 4.00 pm at the Elite Park Avenue Hotel, Kungsportsavenyn 36-38 in Gothenburg, Sweden. The entrance opens at 3.30 pm. Four weeks before the Annual General Meeting, Vitrolife AB (publ) will publish the Annual and sustainability report 2023. In order to safeguard the environment,

    Conference call interim report

    Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q1, 2024. The presentation will be held in English.Time: Thursday 18 April, 2024 at 10.00 a.m. CET. To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy | Vitrolife Group 

    Vitrolife Group Annual and Sustainability Report 2023

    Vitrolife Group has today published its Annual and Sustainability Report for 2023.The Annual and Sustainability Report is now available digitally in English and Swedish at www.vitrolifegroup.com. The Annual Report in accordance with European Single Electronic Format (ESEF) is available in Swedish. Vitrolife Group has chosen not to print or distribute a hard copy of the Annual Report. Those who are unable to access the Annual Report digitally can request a print-out of the Annual Report by contacting Vitrolife Group at investors@vitrolife.com or call +46 (0) 31 721 80 00. Gothenburg,

    Notice to attend the Annual General Meeting of Vitrolife AB (publ)

    The shareholders of Vitrolife AB (publ), corporate identity number 556354-3452(‘the Company’) are hereby invited to attend the Annual General Meeting of shareholders on Thursday 25 April 2024 at 4.00 pm at the Elite Park Avenue Hotel, Kungsportsavenyn 36-38 in Gothenburg, Sweden. The entrance opens at 3.30 pm.Shareholders who wish to attend the Annual General Meeting must:-be recorded in the share register prepared by Euroclear Sweden AB relating to the circumstances on 17 April 2024; and-notify their attendance in accordance with the instructions in the Notice by 19 April 2024.

    Fourth quarter and full year report, 2023: Continued growth with margin expansions

    Fourth quarter · Sales of SEK 904 (855) million, an increase of 6%. In local currencies the growth was 5%. · Sales, in local currencies increased by 16% in APAC and 6% in EMEA, while sales in Americas decreased by 5%.  · Sales in local currencies increased by 1% in Consumables and 31% in Technologies, while sales in Genetic Services decreased by 2%. · Gross margin increased to 56.9% (54.2). · Operating income before depreciation and amortisation (EBITDA) was SEK 294 (273) million, giving an EBITDA margin of 32.5% (31.9). · Operating cash flow increased to SEK 171 million

    Conference call full year report 2023

    Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the fourth quarter and full year report 2023. The presentation will be held in English.Time: Friday 2 February, 2024 at 10.00 a.m. CET. To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy | Vitrolife Group 

    Vitrolife Group makes an impairment charge of SEK 4.3 billion relating to Igenomix and provides preliminary financials for the fourth quarter 2023

    · Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021. · Igenomix, now known as the business area Genetic Services, remains a core part of the new corporate strategy for the Vitrolife Group, however we have challenges to navigate in the short term. · Vitrolife Group also announces preliminary figures for Q4, with sales of SEK 904 million, corresponding to 6% growth in SEK, gross margin of 56.9% and EBITDA margin of 32.5%. Non-cash impairment charge Vitrolife Group (NASDAQ:

    Vitrolife Group unveils new corporate strategy and updates long-term financial objectives at Capital Markets Day

    Vitrolife AB (publ) today is hosting a Capital Markets Day presentation for the investment community in Stockholm, Sweden, from 10:00-15:30 CETBronwyn Brophy, Chief Executive Officer, Patrik Tolf, Chief Financial Officer, and members of the wider Vitrolife Group leadership team will present the company mission to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. The Group will achieve this through execution of a new corporate strategy to drive long-term, sustainable, profitable growth by focusing on five key strategic pillars: •

    Vitrolife Group to host Capital Markets Day on 12 December 2023

    Vitrolife AB (publ) today announced that it will host a Capital Markets Day presentation for the investment community on 12 December 2023, 10:00-15:30 CET in Stockholm.Bronwyn Brophy, Chief Executive Officer, and Patrik Tolf, Chief Financial Officer, will be joined by leading experts and practitioners in the reproductive health industry to share their thoughts on the future of infertility care around the world. The Executive Management team will set out the new corporate strategy to drive sustainable, profitable growth capitalising on the mega market trends and leveraging the Vitrolife

    Interim report Q3, 2023: Profitable growth globally despite headwind in the U.S.

    Third quarter · Sales of SEK 848 (798) million, an increase of 6%, or 7% excluding discontinued business. In local currencies the growth was 2% and excluding discontinued business 3%. · Sales, in local currencies and excluding discontinued business, increased by 5% in APAC and 14% in EMEA, while Americas decreased by 8%. · Sales, in local currencies and excluding discontinued business, increased by 8% in Consumables and 14% in Technologies, while Genetic Services decreased by 5%. · Gross margin increased to 55.7% (53.6). · Operating income before depreciation and

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe